The excessive and aberrant use of MET in cancer is readily observed in [<sup>11</sup>C]-MET-PET imaging, where high uptake of [<sup>11</sup>C]-MET results in a very strong and selective tumor signal compared to normal tissue background for brain cancer and possibly other cancers.
MET-PET is not widely used in the United States, though clinical trials from Japan and Germany suggesting the diagnostic ability of MET-PET imaging are superior to FDG-PET imaging for brain tumors.
The purpose of this study was to investigate the not-well-known molecular determinants that predict responsiveness to c-MET inhibitors and to explore new strategies for improving inhibitor efficacy in brain tumors.
The hepatocyte growth factor (HGF)/MET pathway has an established role in both normal cerebellar development as well as the development and progression of human brain tumors, including MB.